858 Therapeutics
858 Therapeutics is a clinical-stage biotechnology company based in San Diego, California, developing first-in-class and best-in-class small-molecule therapies that target tumor dependencies in DNA damage response (DDR) pathways. Its lead program, ETX-19477, is an oral, potent, and selective PARG (p
858 Therapeutics is an API provider whose private shares are listed on 2 secondary markets: EquityZen, Nasdaq Private Market.
Where It Trades
Listing data is compiled from the public marketplace pages of Forge Global, Hiive, EquityZen, Nasdaq Private Market, and Augment. A listing indicates that a venue has published a page for this company — it is not an offer, a quote, or investment advice, and APIs.io has no affiliation with any venue.
Work with this as data
Every listing here is available over the APIs.io API and to AI agents over MCP. Secondary Market is not yet its own endpoint on the v1 API. Reach it through catalog search and the tag graph, or the MCP server.